|
|
Дата |
|---|
| 23:08 |
| 16.11.2026 |
| 13.11.2026 |
| 12.11.2026 |
| 11.11.2026 |
| 10.11.2026 |
| 09.11.2026 |
| 06.11.2026 |
| 05.11.2026 |
| 04.11.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
14.60
|
14.69
|
11.97
|
11.58
|
14.71
|
14.645
|
|
|
5 505 050.48
|
4 124.00
|
|
11.87
|
12.08
|
12.69
|
11.345
|
12.94
|
11.85
|
|
|
5 578 086.44
|
5 571.00
|
|
12.64
|
13.00
|
15.06
|
12.6801
|
15.06
|
13.10
|
|
|
3 758 200.16
|
3 152.00
|
|
14.50
|
14.84
|
15.39
|
14.0201
|
15.39
|
14.84
|
|
|
7 166 176.19
|
4 466.00
|
|
14.90
|
16.38
|
14.87
|
13.96
|
15.85
|
15.385
|
|
|
5 423 530.86
|
4 742.00
|
|
15.00
|
15.50
|
14.47
|
12.80
|
15.01
|
14.78
|
|
|
12 499 144.28
|
8 540.00
|
|
15.64
|
16.11
|
10.06
|
9.90
|
13.47
|
13.38
|
|
|
11 159 211.04
|
8 424.00
|
|
10.06
|
10.48
|
11.52
|
9.60
|
11.8392
|
10.17
|
|
|
6 880 425.21
|
5 654.00
|
|
10.20
|
12.00
|
13.16
|
10.55
|
13.22
|
11.64
|
|
|
8 737 710.10
|
6 870.00
|
|
13.30
|
14.10
|
13.80
|
13.1454
|
13.96
|
13.40
|
|
|
3 982 916.13
|
3 628.00
|
Iambic Therapeutics, Inc. is a technology and clinical-stage life sciences company. Its molecular superintelligence platform integrates proprietary AI technologies with automated, scalable chemistry and biology experimentation. Its pipeline of drug candidates is developed using a molecular superintelligence platform. IAM1363, is a HER2 inhibitor that is in a Phase I/Ib clinical trial in subjects with HER2-altered solid tumors. The Company's additional programs, IAM217 (KIF18A inhibitor) and IAM-C1 (dual CDK2/4 inhibitor), are in preclinical development. IAM1363 is an oral, selective, pan-mutant, and brain-penetrant small molecule inhibitor that selectively targets HER2 and HER2 mutants, while sparing EGFR.
Amplification and mutations of HER2 drive a wide range of human cancers. IAM-C1 is a small-molecule inhibitor with a differentiated selectivity profile, designed to specifically target CDK2 and CDK4, two cell-cycle kinases that are frequently dysregulated in various cancers.
Показать все Скрыть